Previous Article | Next Article 
Journal of Virology, March 2001, p. 2857-2865, Vol. 75, No. 6
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.6.2857-2865.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Replicating Adenoviruses That Target Tumors with
Constitutive Activation of the wnt Signaling Pathway
Michele
Brunori,
Maddalena
Malerba,
Haruhiko
Kashiwazaki,
and
Richard
Iggo*
Swiss Institute for Experimental Cancer Research
(ISREC), 1066 Epalinges, Switzerland
Received 11 October 2000/Accepted 24 December 2000
Despite important advances in understanding the molecular basis of
cancer, few treatments have been devised which rationally target known
causal oncogenic defects. Selectively replicating viruses have a major
advantage over nonreplicating viruses to target these defects because
the therapeutic effect of the injected virus is augmented by virus
produced within the tumor. To permit rational targeting of colon
tumors, we have developed replicating adenoviruses that express the
viral E1B and E2 genes from promoters controlled by the Tcf4
transcription factor. Tcf4 is constitutively activated by mutations in
the adenomatous polyposis coli and
-catenin genes in virtually all
colon tumors and is constitutively repressed by Groucho and CtBP in
normal tissue. The Tcf-E2 and Tcf-E1B promoters are active in many, but
not all, cell lines with activation of the wnt pathway. Viruses with
Tcf regulation of E2 expression replicate normally in SW480 colon
cancer cells but show a 50- to 100-fold decrease in replication in
H1299 lung cancer cells and WI38 normal fibroblasts. Activation of wnt
signaling by transduction of a stable
-catenin mutant into normal
fibroblasts renders the cells permissive for virus replication.
Insertion of Tcf4 sites in the E1B promoter has only small effects on
replication in vitro but significantly reduces the inflammatory
response in a rodent lung model in vivo. Replicating adenoviruses with
Tcf regulation of both E1B and E2 transcription are potentially useful
for the treatment of liver metastases from colorectal tumors, but
additional changes will be required to produce a virus that can be used
to treat all colon tumors.
*
Corresponding author. Mailing address: Swiss Institute
for Experimental Cancer Research (ISREC), Boveresses 155, 1066 Epalinges, Switzerland. Phone: 41 21 692 5889. Fax: 41 21 652 6933. E-mail: Richard.Iggo{at}isrec.unil.ch.

Present address: Section of Oral & Maxillofacial Surgery, Division
of Cancer-Related Genes, Institute for Genetic Medicine,
Hokkaido
University, Kita-ku, Sapporo City, Hokkaido 060-8586,
Japan.
Journal of Virology, March 2001, p. 2857-2865, Vol. 75, No. 6
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.6.2857-2865.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Peerlinck, I., Merron, A., Baril, P., Conchon, S., Martin-Duque, P., Hindorf, C., Burnet, J., Quintanilla, M., Hingorani, M., Iggo, R., Lemoine, N. R., Harrington, K., Vassaux, G.
(2009). Targeted Radionuclide Therapy Using a Wnt-Targeted Replicating Adenovirus Encoding the Na/I Symporter. Clin. Cancer Res.
15: 6595-6601
[Abstract]
[Full Text]
-
Shin, J., Bae, D. R., Latshaw, J. D., Wick, M. P., Reddish, J. M., Lee, K.
(2009). Technical note: A gene delivery system in the embryonic cells of avian species using a human adenoviral vector. J ANIM SCI
87: 2791-2795
[Abstract]
[Full Text]
-
Kuroda, T., Rabkin, S. D., Martuza, R. L.
(2006). Effective Treatment of Tumors with Strong {beta}-Catenin/T-Cell Factor Activity by Transcriptionally Targeted Oncolytic Herpes Simplex Virus Vector.. Cancer Res.
66: 10127-10135
[Abstract]
[Full Text]
-
Hoffmann, D., Wildner, O.
(2006). Enhanced killing of pancreatic cancer cells by expression of fusogenic membrane glycoproteins in combination with chemotherapy.. Molecular Cancer Therapeutics
5: 2013-2022
[Abstract]
[Full Text]
-
Hoffmann, D., Wildner, O.
(2006). Restriction of adenoviral replication to the transcriptional intersection of two different promoters for colorectal and pancreatic cancer treatment.. Molecular Cancer Therapeutics
5: 374-381
[Abstract]
[Full Text]
-
Homicsko, K., Lukashev, A., Iggo, R. D.
(2005). RAD001 (Everolimus) Improves the Efficacy of Replicating Adenoviruses that Target Colon Cancer. Cancer Res.
65: 6882-6890
[Abstract]
[Full Text]
-
Toth, K., Djeha, H., Ying, B., Tollefson, A. E., Kuppuswamy, M., Doronin, K., Krajcsi, P., Lipinski, K., Wrighton, C. J., Wold, W. S. M.
(2004). An Oncolytic Adenovirus Vector Combining Enhanced Cell-to-Cell Spreading, Mediated by the ADP Cytolytic Protein, with Selective Replication in Cancer Cells with Deregulated Wnt Signaling. Cancer Res.
64: 3638-3644
[Abstract]
[Full Text]
-
Banerjee, N. S., Rivera, A. A., Wang, M., Chow, L. T., Broker, T. R., Curiel, D. T., Nettelbeck, D. M.
(2004). Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures. Molecular Cancer Therapeutics
3: 437-449
[Abstract]
[Full Text]
-
Malerba, M., Daeffler, L., Rommelaere, J., Iggo, R. D.
(2003). Replicating Parvoviruses That Target Colon Cancer Cells. J. Virol.
77: 6683-6691
[Abstract]
[Full Text]
-
Suzuki, K., Alemany, R., Yamamoto, M., Curiel, D. T.
(2002). The Presence of the Adenovirus E3 Region Improves the Oncolytic Potency of Conditionally Replicative Adenoviruses. Clin. Cancer Res.
8: 3348-3359
[Abstract]
[Full Text]
-
Tsukuda, K., Wiewrodt, R., Molnar-Kimber, K., Jovanovic, V. P., Amin, K. M.
(2002). An E2F-responsive Replication-selective Adenovirus Targeted to the Defective Cell Cycle in Cancer Cells: Potent Antitumoral Efficacy but No Toxicity to Normal Cell. Cancer Res.
62: 3438-3447
[Abstract]
[Full Text]
-
Ring, C. J. A.
(2002). Cytolytic viruses as potential anti-cancer agents. J. Gen. Virol.
83: 491-502
[Abstract]
[Full Text]